Results 51 to 60 of about 6,238,612 (332)
Annals of Hepatology, 2003 Introduction: The course of HBV infection and the outcome of interferon alpha (IFNα) therapy of patients with chronic hepatitis B, is determined by the antiviral immune response of the host.
Magdalena Góra-Gębka, MD, PhD +4 more
doaj +1 more source
Reciprocal control of viral infection and phosphoinositide dynamics
FEBS Letters, EarlyView.Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley +1 more source
Molecular cloning of cat interleukin-12 [PDF]
Immunogenetics, 1997 The recently discovered interleukin-12 (IL-12) is a heterodimeric 70000 Mr cytokine composed of a disulphide-bonded 35000 Mr (p35) subunit and a 40000 Mr (p40) subunit. Produced mainly by activated monocytes/macrophages and B cells, it enhances NK/LAK cell cytolytic activity and stimulates cytotoxic T-cell responses and IFN-γ production.
Horzinek, M.C. +3 more
openaire +3 more sources
Function‐driven design of a surrogate interleukin‐2 receptor ligand
FEBS Letters, EarlyView.Interleukin (IL)‐2 signaling can be achieved and precisely fine‐tuned through the affinity, distance, and orientation of the heterodimeric receptors with their ligands. We designed a biased IL‐2 surrogate ligand that selectively promotes effector T and natural killer cell activation and differentiation. Interleukin (IL) receptors play a pivotal role in
Ziwei Tang +9 more
wiley +1 more source
Interleukin-12 and protective immunity to schistosomes
Brazilian Journal of Medical and Biological Research, 1998 The attenuated vaccine against Schistosoma mansoni induces Th1-mediated protective immunity and we have sought to identify a role for IL-12 in this model.
A.P. Mountford, V.L. Shires, S. Anderson
doaj +1 more source
Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine
Molecular Oncology, EarlyView.The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu +18 more
wiley +1 more source
Memorias do Instituto Oswaldo Cruz, 2004 Resistance to infection by Leishmania major has been associated with the development of a Th1 type response that is dependent on the presence of interleukin 12 (IL-12).
Sebastião Martins de Souza-Neto +3 more
doaj +1 more source
mAbs, 2023 There are no effective treatment options for most patients with metastatic colorectal cancer (mCRC). mCRC remains a leading cause of tumor-related death, with a five-year survival rate of only 15%, highlighting the urgent need for novel pharmacological ...
Louis Plüss +10 more
doaj +1 more source
Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12 [PDF]
, 2001 Despite the efficacy of IL-12 in cancer experimental models, clinical trials with systemic recombinant IL-12 showed unacceptable toxicity related to endogenous IFNgamma production.
Mazzolini, G. (Guillermo) +8 more
core +1 more source
Molecular Oncology, EarlyView.This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad +17 more
wiley +1 more source